logo
NatureVest Celebrates a Decade of Impact

NatureVest Celebrates a Decade of Impact

For more than a decade, NatureVest, The Nature Conservancy's (TNC) in-house impact investing and sustainable finance team, has been harnessing the power of private capital to drive conservation at scale. Thanks to the support of our colleagues and collaborators, our impact investment portfolio demonstrates how investing in nature is smart business strategy, pairing meaningful returns with measurable impacts.
As we mark the 10th anniversary of NatureVest with this 2024 Impact Report, I am filled with immense pride and gratitude. In our early years, we embarked on pioneering projects like Livestock to Markets, to improve herding practices and land management, and the Olympic Peninsula Acquisition Project for sustainable forest management and restoration. These early projects helped lay the foundation for our ambitious vision. Now, a decade later, our portfolio has grown to represent USD 3.5 billion in committed capital, with projects spanning four continents and covering a variety of asset types. This remarkable progress highlights the unwavering commitment of our team, partners, investors, and collaborators. Reflecting on how far we have come, I extend my heartfelt thanks to all who have been an integral part of this journey.
What's Inside the Report?
New Deals: The report highlights TNC's latest impact investment projects, including the Blue Revolution Fund and Bahamas Nature Bonds. These initiatives illustrate how collaboration among partners and investors creates new opportunities for conservation funding and impact.
Conservation Updates: We explore the latest developments across the Cumberland Forest Project, the Sustainable Water Impact Fund, the Africa Conservation and Communities Tourism Fund, and our BTG Pactual Timberland Investment Group (TIG) and TNC Collaboration. This year, our updates focus on how conservation efforts can diversify revenue streams while achieving environmental and social outcomes.
Impact Investing Interview: The interview titled 'Built to Last: Building Impact into Investment Structures' features Glen Jeffries, NatureVest's managing director of impact investments. He describes how NatureVest integrates impact into a project's structure to ensure outcomes for nature. Here, readers can learn about the three Ps as well as answers to questions like: How do you balance returns with impact objectives when structuring a deal?
Outcomes: We explore each project's impact targets and realized impact to date. Be sure to check out the Appendices to see the results of our collective work. Across our growing portfolio, we are excited to report significant wins for nature and people.
We express our deepest thanks to our colleagues across TNC, as well as the partners and investors who make these transformative transactions and their positive outcomes possible. We also extend our gratitude to all our readers for your continued support and interest in our mission.
By Catherine Burns, Interim Managing Director, NatureVest
Visit 3BL Media to see more multimedia and stories from NatureVest

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Flex LNG - Ex Date Q1 2025
Flex LNG - Ex Date Q1 2025

Yahoo

time31 minutes ago

  • Yahoo

Flex LNG - Ex Date Q1 2025

HAMILTON, Bermuda, June 5, 2025 /PRNewswire/ -- The shares in Flex LNG Ltd. (Ticker: FLNG) traded on Oslo Stock Exchange ("OSE") and registered with Euronext Securities Oslo will trade ex dividend of USD 0.75 per share as of today, June 5, 2025. The dividend will be paid to shareholders on OSE on or about June 25, 2025. The shares traded on the New York Stock Exchange ("NYSE") will be traded ex dividend of USD 0.75 per share on June 6, 2025. The dividend will be paid to shareholders on NYSE on or about June 20, 2025. For further information, please contact: Mr. Knut Traaholt, Chief Financial Officer of Flex LNG Management AS Telephone: +47 23 11 40 00Email: ir@ About Flex LNG Flex LNG is a shipping company focused on the growing market for Liquefied Natural Gas (LNG). Our fleet consists of thirteen LNG carriers on the water and all of our vessels are state-of-the-art ships with the latest generation two-stroke propulsion (MEGI and X-DF). These modern ships offer significant improvements in fuel efficiency and thus also carbon footprint compared to the older steam and four-stroke propelled ships. Flex LNG is listed on the New York Stock Exchange as well as Oslo Stock Exchange under the ticker FLNG. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This information was brought to you by Cision View original content: SOURCE Flex LNG Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea

Yahoo

time38 minutes ago

  • Yahoo

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea

Allschwil, Switzerland, June 05, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering the second USD 2.5 million milestone payment this year. David Veitch, Basilea's Chief Executive Officer, stated: 'This milestone payment for the Asia Pacific region, including China, reflects the strong and growing global demand for novel antifungal therapies. Continued growth of Cresemba, particularly in China, where uptake has been especially robust, reinforces its significant clinical value for patients facing life-threatening infections. We congratulate our partner Pfizer for their ongoing commitment to making Cresemba available to patients in need.' The license agreement between Basilea and Pfizer for Cresemba covers Europe (excluding the Nordic countries) as well as China and 16 countries in the Asia Pacific region. Cresemba is marketed in more than 70 countries. According to the latest available market data, total global in-market sales of Cresemba in the twelve-month period between January and December 2024 amounted to USD 562 million, a 19 percent growth year-on-year, making it the largest branded antifungal for invasive fungal infections worldwide.1 About Cresemba® (isavuconazole) Cresemba, with the active ingredient isavuconazole, is an intravenous (i.v.) and oral azole antifungal. Basilea has entered into several license and distribution agreements for Cresemba covering approximately 115 countries. In China, the oral and intravenous formulations are approved for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis. Isavuconazole is also approved in the European Union2, the United Kingdom3, the United States (US)4 and several additional countries including in the Asia Pacific region.5 About Basilea Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial or fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit Disclaimer This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For further information, please contact: Peer Nils Schröder, PhDHead of Corporate Communications & Investor RelationsBasilea Pharmaceutica International Ltd, Allschwil Hegenheimermattweg 167b4123 AllschwilSwitzerland Phone +41 61 606 1102 E-mail media_relations@ This press release can be downloaded from References IQVIA Analytics Link, December 2024. In-market sales reported as moving annual total (MAT) in US dollar. European Public Assessment Report (EPAR) Cresemba: [Accessed: June 04, 2025] Summary of Product Characteristics (SmPC) Cresemba: [Accessed: June 04, 2025] Full US prescribing information: [Accessed: June 04, 2025] The registration status and approved indications may vary from country to country. Attachment Press release (PDF)

Global Anticancer Drugs Market Booms with 11.3% CAGR, Driven by Targeted Therapy & Biomarkers
Global Anticancer Drugs Market Booms with 11.3% CAGR, Driven by Targeted Therapy & Biomarkers

Yahoo

time2 hours ago

  • Yahoo

Global Anticancer Drugs Market Booms with 11.3% CAGR, Driven by Targeted Therapy & Biomarkers

Anticancer Drugs Market is Segmented by Type (Cancer Immunotherapy, Targeted Therapy, Chemotherapy), by Application (Lung Cancer, Breast Cancer, Prostate Cancer, Blood-related Cancer). BANGALORE, India, June 5, 2025 /PRNewswire/ -- The global market for Anticancer Drugs was valued at USD 206090 Million in the year 2024 and is projected to reach a revised size of USD 430540 Million by 2031, growing at a CAGR of 11.3% during the forecast period. Claim Your Free Report: Major Factors Driving the Growth of Anticancer Drugs Market: The anticancer drugs market is experiencing robust growth fueled by rising cancer incidence, expanding treatment options, and technological advances. With increasing adoption of personalized medicine, immunotherapy, and biosimilars, the landscape is evolving rapidly. Pharmaceutical companies are heavily investing in R&D to develop drugs targeting various cancer types, leading to a strong pipeline. Regulatory agencies are offering expedited approvals for breakthrough therapies, encouraging innovation. The market encompasses chemotherapy, targeted therapy, hormone therapy, and biologics, catering to both early and advanced-stage cancers. As cancer becomes a global health priority, the demand for accessible, effective, and cost-efficient treatment solutions is expected to grow steadily, sustaining long-term market expansion. Unlock Insights: View Full Report Now! TRENDS INFLUENCING THE GROWTH OF THE ANTICANCER DRUGS MARKET: Cancer immunotherapy is significantly propelling the growth of the anticancer drugs market due to its ability to harness the body's immune system to combat malignant cells more effectively than traditional methods. Unlike chemotherapy, which often damages healthy cells, immunotherapy offers targeted action with fewer side effects, increasing patient preference and clinician recommendation. The emergence of immune checkpoint inhibitors, CAR T-cell therapies, and monoclonal antibodies has broadened treatment options across multiple cancer types. Its success in treating cancers that were previously resistant to standard therapies has generated strong clinical interest. Additionally, rising investments, expanding FDA approvals, and ongoing research collaborations between biotech firms and pharmaceutical companies are further accelerating the market demand for immunotherapy-based anticancer drugs. Targeted therapy is a crucial driver in the anticancer drugs market as it allows for the development of treatments designed to interfere with specific molecular targets associated with cancer progression. This precision-based approach minimizes damage to healthy tissues and improves the effectiveness of cancer treatment. Innovations in genomics and molecular diagnostics have enabled oncologists to identify mutations and biomarkers, leading to tailored therapies for individuals. Drugs targeting proteins like HER2, EGFR, and BRAF are now standard in treating cancers like breast, lung, and melanoma. With fewer side effects and improved patient outcomes, targeted therapies are preferred over conventional cytotoxic drugs. As personalized medicine gains ground globally, targeted therapy continues to fuel steady market expansion. Lung cancer remains a dominant force in driving the anticancer drugs market due to its high global incidence and mortality rate. The complex nature of lung cancer requires a broad arsenal of treatment options, including chemotherapy, targeted therapies, and immunotherapies. With advancements in early detection and biomarker testing, patients are now eligible for precision treatments that significantly improve survival rates. Governments and healthcare agencies are increasing screening programs, particularly in high-risk populations like smokers and the elderly, driving diagnosis rates and treatment uptake. The introduction of novel drugs for advanced stages of lung cancer and increased awareness has led to growing demand, significantly contributing to market revenue. The steady increase in global cancer cases is a primary factor propelling the anticancer drugs market. Factors such as aging populations, lifestyle changes, exposure to carcinogens, and rising obesity rates are contributing to this surge. According to WHO, cancer is now one of the leading causes of death globally, placing immense pressure on healthcare systems to deliver effective treatments. This rising demand compels pharmaceutical companies to accelerate drug development and approval pipelines. Public and private funding for cancer research is also increasing to support this urgency. As a result, the anticancer drugs market is expanding to cater to diverse cancer types and stages, creating a consistent need for innovative and accessible therapies. Government initiatives and healthcare policies play a vital role in boosting the anticancer drugs market. Many countries are expanding public healthcare coverage for cancer treatment, especially in developed regions like North America and Europe. Subsidized treatment programs and insurance reimbursements have made costly anticancer therapies more accessible to a broader patient base. Special provisions for rare cancers and orphan drug designations further incentivize pharmaceutical firms to innovate. Public institutions like the National Cancer Institute (NCI) and Cancer Research UK are increasing investments in clinical trials and drug discovery. Such funding and supportive policies reduce the financial burden on patients and encourage consistent demand for effective cancer medications. Biomarker research is revolutionizing how anticancer drugs are developed, prescribed, and monitored. Biomarkers help predict disease progression, treatment response, and potential side effects, allowing clinicians to personalize therapies for better outcomes. Companion diagnostics, often co-developed with anticancer drugs, guide targeted treatment decisions, improving precision and efficacy. The integration of biomarkers in clinical trials accelerates drug approvals by identifying suitable patient cohorts. This has led to faster commercialization of breakthrough therapies. Biomarker-driven treatments also reduce trial-and-error prescribing, improving healthcare efficiency. As the field of precision oncology expands, biomarker research is becoming indispensable, thereby acting as a powerful growth catalyst for the anticancer drugs market. Emerging markets across Asia, Latin America, and Africa are witnessing improved healthcare infrastructure, which supports wider access to cancer diagnosis and treatment. Governments are investing in public hospitals, telemedicine services, and awareness campaigns to facilitate early detection and treatment. Pharmaceutical companies are also forming partnerships in these regions to launch affordable versions of branded therapies. Access to generics and biosimilars further supports affordability. Mobile health technologies and e-pharmacies are helping bridge urban-rural gaps in drug delivery. With growing income levels and rising cancer burden in these regions, the demand for anticancer drugs is expanding. This regional growth trend adds significant momentum to the global market. Claim Yours Now! ANTICANCER DRUGS MARKET SHARE Global key players of Anticancer Drugs include Merck & Co, Bristol-Myers Squibb, Roche, Novartis, Johnson & Johnson, etc. The top five players hold a share over 55%. North America is the largest market, and has a share of about 55%, followed by Asia-Pacific and Europe with 21% and 19%, separately. Regionally, North America leads the anticancer drugs market due to its advanced healthcare infrastructure, high cancer prevalence, and strong research funding. The U.S. accounts for a significant share, with widespread access to innovative therapies and insurance coverage. In terms of product type, Targeted Therapy is the largest segment, occupied for a share of 58%. In terms of application, Blood-related Cancer has a share of about 23 percent. Key Companies: Novartis Pfizer Inc Amgen Inc Astrazeneca plc Merck AbbVie Johnson & Johnson Gilead Sciences Roche Bristol–Myers Squibb Takeda Merck KGaA Seagen Eli Lilly Ono Pharmaceutical GSK Exelixis Inc Regeneron Innovent Hengrui Medicine Purchase Regional Report: SUBSCRIPTION We have introduced a tailor-made subscription for our customers. Please leave a note in the Comment Section to know about our subscription plans. DISCOVER MORE INSIGHTS: EXPLORE SIMILAR REPORTS! - Anthracycline Anticancer Drugs Market - The global market for Platinum-based Anticancer Drugs was estimated to be worth USD 1541.9 Million in 2023 and is forecast to a readjusted size of USD 1788.9 Million by 2030 with a CAGR of 2.1% during the forecast period 2024-2030. - Oncology Generic Injectable Drugs Market - Ovarian Cancer Treatment Drugs Market - Alkylating Agent Antineoplastic Drugs Market - The global Oncology Drugs Market revenue was USD 197440 Million in 2022 and is forecast to a readjusted size of USD 395270 Million by 2029 with a CAGR of 10.3% during the review period (2023-2029). - The global market for Oncology Treatment Drug was estimated to be worth USD 197440 Million in 2023 and is forecast to a readjusted size of USD 342140 Million by 2030 with a CAGR of 8.0% during the forecast period 2024-2030. - Esophageal Cancer Drugs Market - Mylotarg Market - Pharmaceutical Grade Anhydrous Piperazine Market - Platinum-based Anticancer APIs Market DISCOVER OUR VISION: VISIT ABOUT US! Valuates offers in-depth market insights into various industries. Our extensive report repository is constantly updated to meet your changing industry analysis needs. Our team of market analysts can help you select the best report covering your industry. We understand your niche region-specific requirements and that's why we offer customization of reports. With our customization in place, you can request for any particular information from a report that meets your market analysis needs. To achieve a consistent view of the market, data is gathered from various primary and secondary sources, at each step, data triangulation methodologies are applied to reduce deviance and find a consistent view of the market. Each sample we share contains a detailed research methodology employed to generate the report. Please also reach our sales team to get the complete list of our data sources. GET A FREE QUOTE Valuates Reportssales@ U.S. Toll-Free Call 1-(315)-215-3225WhatsApp: +91-9945648335Website: Logo: View original content to download multimedia: SOURCE Valuates Reports Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store